 |
|
LESS IS MORE
Proton Pump Inhibitors and Risk for Recurrent Clostridium difficile Infection
Amy Linsky, MD;
Kalpana Gupta, MD, MPH;
Elizabeth V. Lawler, DSc;
Jennifer R. Fonda, MA;
John A. Hermos, MD
Arch Intern Med. 2010;170(9):772-778.
Background Proton pump inhibitors (PPIs) are widely used gastric acid suppressants, but they are often prescribed without clear indications and may increase risk of Clostridium difficile infection (CDI). We sought to determine the association between PPI use and the risk of recurrent CDI.
Methods Retrospective, cohort study using administrative databases of the New England Veterans Healthcare System from October 1, 2003, through September 30, 2008. We identified 1166 inpatients and outpatients with metronidazole- or vancomycin hydrochloride–treated incident CDI, of whom 527 (45.2%) received oral PPIs within 14 days of diagnosis and 639 (54.8%) did not. We determined the hazard ratio (HR) for recurrent CDI, defined by a positive toxin finding in the 15 to 90 days after incident CDI.
Results Recurrent CDI was more common in those exposed to PPIs than in those not exposed (25.2% vs 18.5%). Using Cox proportional survival methods, we determined that the adjusted HR of recurrent CDI was greater in those exposed to PPIs during treatment (1.42; 95% confidence interval [CI], 1.11-1.82). Risks among exposed patients were highest among those older than 80 years (HR, 1.86; 95% CI, 1.15-3.01) and those receiving antibiotics not targeted to C difficile during follow-up (HR, 1.71; 95% CI, 1.11-1.64).
Conclusions Proton pump inhibitor use during incident CDI treatment was associated with a 42% increased risk of recurrence. Our findings warrant further studies to examine this association and careful consideration of the indications for prescribing PPIs during treatment of CDI.
Author Affiliations: Section of General Internal Medicine, Department of Medicine, Boston Medical Center (Drs Linsky and Hermos), Massachusetts Veterans Epidemiology Research and Information Center, Veterans Affairs Cooperative Studies Program, Veterans Affairs Boston Healthcare System (Drs Gupta, Lawler, and Hermos and Ms Fonda), Section of Infectious Diseases (Dr Gupta), Department of Medicine (Dr Hermos), Boston University School of Medicine, and Department of Medicine, Harvard Medical School (Dr Lawler), Boston, Massachusetts.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Failing the Acid Test: Benefits of Proton Pump Inhibitors May Not Justify the Risks for Many Users
Mitchell H. Katz
Arch Intern Med. 2010;170(9):747-748.
EXTRACT
| FULL TEXT
Less Is More: How Less Health Care Can Result in Better Health
Deborah Grady and Rita F. Redberg
Arch Intern Med. 2010;170(9):749-750.
EXTRACT
| FULL TEXT
High-Dose vs Non–High-Dose Proton Pump Inhibitors After Endoscopic Treatment in Patients With Bleeding Peptic Ulcer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Chih-Hung Wang, Matthew Huei-Ming Ma, Hao-Chang Chou, Zui-Shen Yen, Chih-Wei Yang, Cheng-Chung Fang, and Shyr-Chyr Chen
Arch Intern Med. 2010;170(9):751-758.
ABSTRACT
| FULL TEXT
Proton Pump Inhibitor Use, Hip Fracture, and Change in Bone Mineral Density in Postmenopausal Women: Results From the Women's Health Initiative
Shelly L. Gray, Andrea Z. LaCroix, Joseph Larson, John Robbins, Jane A. Cauley, JoAnn E. Manson, and Zhao Chen
Arch Intern Med. 2010;170(9):765-771.
ABSTRACT
| FULL TEXT
Proton Pump Inhibitors for Prophylaxis of Nosocomial Upper Gastrointestinal Tract Bleeding: Effect of Standardized Guidelines on Prescribing Practice
Patrick S. Yachimski, Elizabeth A. Farrell, Daniel P. Hunt, and Andrea E. Reid
Arch Intern Med. 2010;170(9):779-783.
ABSTRACT
| FULL TEXT
Iatrogenic Gastric Acid Suppression and the Risk of Nosocomial Clostridium difficile Infection
Michael D. Howell, Victor Novack, Philip Grgurich, Diane Soulliard, Lena Novack, Michael Pencina, and Daniel Talmor
Arch Intern Med. 2010;170(9):784-790.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Risk of Community-Acquired Pneumonia in Veteran Patients to Whom Proton Pump Inhibitors Were Dispensed
Hermos et al.
Clinical Infectious Diseases 2012;54:33-42.
ABSTRACT
| FULL TEXT
Risk Factors Associated With Complications and Mortality in Patients With Clostridium difficile Infection
Morrison et al.
Clinical Infectious Diseases 2011;53:1173-1178.
ABSTRACT
| FULL TEXT
Clostridium difficile in the ICU: The Struggle Continues
Bobo et al.
Chest 2011;140:1643-1653.
ABSTRACT
| FULL TEXT
Laboratory Testing for Clostridium difficile Infection: Light at the End of the Tunnel
Peterson et al.
Am J Clin Pathol 2011;136:372-380.
ABSTRACT
| FULL TEXT
Risk of infections in rheumatoid arthritis patients treated with tocilizumab
Lang et al.
Rheumatology (Oxford) 2011;0:ker223v1-ker223.
ABSTRACT
| FULL TEXT
Severe occult upper gastrointestinal haemorrhage--a case report
Agha and Agha
QJM 2011;0:hcr085v1-hcr085.
FULL TEXT
Opportunities to Decrease Inappropriate Uses of Proton Pump Inhibitors: Comment on "Proton Pump Inhibitor Use and the Antifracture Efficacy of Alendronate"
Katz
Arch Intern Med 2011;171:1004-1005.
FULL TEXT
PPIs: too much of a good thing?
DTB 2011;49:49-49.
FULL TEXT
Pharmacology Review: Pharmacotherapy for Gastroesophageal Reflux Disease
Hibbs
Neoreviews 2011;12:e159-e166.
ABSTRACT
| FULL TEXT
Reducing NSAID-induced gastrointestinal complications
DTB 2011;49:18-21.
ABSTRACT
| FULL TEXT
Use of Proton Pump Inhibitors and Mortality Among Institutionalized Older People
Bell et al.
Arch Intern Med 2010;170:1604-1605.
FULL TEXT
Proton-Pump Inhibitor Dosing and Negative Consequences
JWatch General 2010;2010:2-2.
FULL TEXT
Recurrent Clostridium difficile Infection and Proton-Pump Inhibitors
JWatch Gastroenterology 2010;2010:4-4.
FULL TEXT
Failing the Acid Test: Benefits of Proton Pump Inhibitors May Not Justify the Risks for Many Users
Katz
Arch Intern Med 2010;170:747-748.
FULL TEXT
Less Is More: How Less Health Care Can Result in Better Health
Grady and Redberg
Arch Intern Med 2010;170:749-750.
FULL TEXT
|
